US-based biotechnology company Casgevy has developed a treatment for sickle cell disease that uses Hemoglobin Edited Blood Cells (CASE). The treatment is a one-time treatment and aims to eliminate debilitating pain that are a hallmark of sickle cell disease. The company said it’s designed to be a one-time treatment and will alleviate symptoms for a…